Home › Compare › LWSOF vs ABBV
LWSOF yields 3.13% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, LWSOF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of LWSOF + ABBV for your $10,000?
Lawson, Inc. operates and franchises convenience stores under the Lawson, Lawson Store 100, and Natural Lawson names in Japan, China, Thailand, Indonesia, the Philippines, and Hawaii. It operates through Domestic Convenience Store Business, Seijo Ishii Business, Entertainment-Related Business, Financial Services Business, and Overseas Business segments. The company's stores provide ready-made dishes, including bento lunchboxes, rice balls, deep-fried items, and salads, as well as coffee and sweets; and over-the-counter pharmaceuticals, prescription drugs, cosmetics, and daily necessities. It also sells tickets for events; and music CD and DVD products, and books through its stores, as well as online. In addition, the company engages in the operation of a chain of supermarkets; management of HMV stores; and operation of United Cinemas movie theaters and MACHI café, as well as ATM at LAWSON stores. Further, the company engages in the banking related business. It operates 14,640 Lawson, Lawson Store 100, and Natural Lawson stores in Japan; 389 United Cinema movie theater screens; 57 HMV stores; 24 nursing care consultation stores; 13,458 LAWSON ATMs; 154 Seijo Ishii supermarket stores; and 335 Lawson hospitals. The company was formerly known as Daiei Convenience Systems, Co. Ltd. and changed its name to Lawson, Inc. in June 1996. The company was founded in 1975 and is headquartered in Tokyo Japan. Lawson, Inc. is a subsidiary of Mitsubishi Corporation.
Full LWSOF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.